Bloomberg

Votes & Verdicts

Business EN ↓ 176 episodes

Votes and Verdicts is a series that examines the intersection of business, policy and law. It features conversations between Bloomberg Intelligence's team of litigation and policy analysts and thought leaders discussing legal and policy issues affecting markets and business decisions across many sectors.

Be sure to visit the podcast's website and support the creator: www.iheart.com

Author

Bloomberg

Category

Business

Podcast website

www.iheart.com

Latest episode

Nov 13, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Berkshire, Google, Pega & Other Catalysts 03.11.2023

Antitrust trials against Google, a court ruling on Meta’s use of teen data and Pegasystems’ Nov. 15 appeal argument to reduce Appan’s $2 billion jury award are key November catalysts to watch. This Bloomberg Intelligence litigation and policy outlook episode, hosted by financials litigation analyst Elliott Stein, gathered the team to discuss these and other catalysts. the trial ends in the DOJ’s s...

Consumer Finance Impact of a CFPB Run Amok 31.10.2023

Bloomberg Intelligence analysts Elliott Stein and Nathan Dean hosted consumer finance lawyer Alan Kaplinsky of Ballard Spahr to discuss the Consumer Financial Protection Bureau’s past, present and future. The conversation included a discussion of the CFPB’s history, its impact on consumer finance companies, how its directors over time have differed, and the pending Supreme Court case challenging t...

Will IRA Drug Pricing Raise Employer Costs? 17.10.2023

Prescription drug negotiation provisions under the Inflation Reduction Act will lower prices on high-cost drugs for the Medicare population, but will it lead to higher or lower expenses on the commercial market? Time will tell, according to Jeff Levin-Scherz, assistant professor at the Harvard T.H. Chan School of Public Health, and Population Health Leader in the Health Management Practice at WTW....

JJCI, Bayer, GSK, Mass Tort Litigation Risks 09.10.2023

Much has been said about companies facing the so-called nuclear verdict in personal injury cases. In this Votes and Verdicts podcast episode, Joseph Fantini, attorney and mass tort expert joins Bloomberg Intelligence litigation analyst Holly Froum to discuss some of the major mass torts facing consumer and industrial companies including Johnson & Johnson Consumer’s Tylenol-autism lawsuits, wee...

Bausch, GBTC, Merck, Meta & Other Catalysts 29.09.2023

A ruling by Oct. 1 in litigation challenging Medicare drug-negotiation provisions under the Inflation Reduction Act, an Oct. 3 Supreme Court argument on the CFPB’s constitutionality and the Department of Justice’s case against the JetBlue-Spirit M&A on Oct. 16 are key catalysts to watch next month. This Bloomberg Intelligence litigation and policy outlook episode of the Votes and Verdicts podc...

AI’s Biggest Legal and Regulatory Questions 26.09.2023

In this follow-up to a March Votes and Verdicts episode about the biggest technology-regulation questions, Bloomberg Intelligene analysts Tamlin Bason and Matt Schettenhelm tackle the issue of artificial intelligence regulation in the US and EU. BI analyst Mandeep Singh joins the podcast to outline the key business models and opportunities tied to AI, as Bason and Schettenhelm walk through how reg...

FTC BioPharma M&A Approach Clashes With Sector 21.09.2023

The Federal Trade Commission’s approach to merger enforcement in the pharmaceutical and biotech industry has become increasingly aggressive. In this episode of the Votes and Verdicts podcast, Goodwin Procter’s Arman Oruc, co-chair of the company’s antitrust and competition practice, and Bloomberg Intelligence biotech analyst Marc Engelsgjerd join host and BI antitrust litigation analyst Jennifer R...

Likelihood Medicare Will Cover Obesity Drugs 05.09.2023

Medicare is prohibited from covering weight loss medications, but recent data showing potential positive health effects could increase pressure on US policymakers to change the law. The cost of removing the prohibition and the potential savings in overall health spending will be important information for Congress to consider before passing any legislation, according to Bill Hoagland, senior vice p...

3M, Drug Pricing, Google and Other Catalysts 30.08.2023

A DOJ antitrust trial v. Google, next steps in the government’s drug-negotiation process under the Inflation Reduction Act and 3M’s PFAS and earplug litigation settlements are key September catalysts to watch. This Bloomberg Intelligence litigation and policy outlook episode, hosted by analyst Elliott Stein, gathered the team to discuss these and other catalysts. In tech, an appeals court decision...

Can Anyone Defeat Trump? Insights on the Forthcoming GOP Debates 17.08.2023

Though the 2024 US elections are still over a year away, forthcoming GOP debates will provide insight on what the elections could mean for markets and policies. In this Votes and Verdicts podcast episode, James Maloney, founding member and Managing Partner of Tiger Hill Partners, a DC-based government-relations company, joins Bloomberg Intelligence Senior Policy Analyst Nathan Dean for a discussio...

3M, Google, Bank Rules, Other 2H Catalysts 21.07.2023

DOJ’s antitrust case v. Google, new bank-capital and internet-ad rules and a 3M earplug trial appeal are key 2H catalysts to watch. This Bloomberg Intelligence litigation and policy outlook episode, hosted by financials litigation analyst Elliott Stein, gathered the team to discuss these and other catalysts. In tech, the Microsoft-Activision M&A will probably close, despite a possible pending...

Craig Burton on Inflation Reduction Act 19.07.2023

The prescription drug negotiation provisions in the Inflation Reduction Act grant the Medicare agency significant regulatory authority to lower prices for high-expenditure drugs, but there’s a high degree of uncertainty as to how the law will impact generic and biosimilar competition, according to Craig Burton, senior vice president of the Association for Accessible Medicines. Burton joins Bloombe...

Why PFAS Legal Risks Persist for 3M, Peers 13.07.2023

Litigation risks continue for manufacturers of PFAS, including 3M, DuPont, Chemours and others, despite 3M’s proposed class action settlement announced in June for $10.5-$12.5 billion and DuPont and Chemours’ deal for $1.2 billion. In this Votes and Verdicts podcast episode, leading remediation technology expert Scott Wilson of Regenesis, a global leader in environmental technology, joins Bloomber...

Why a TikTok Ban Faces a Major Legal Hurdle 06.06.2023

A major legal hurdle -- the First Amendment – stands between lawmakers’ rhetoric and the reality of a TikTok ban. The app’s rocky congressional hearing in March led some Wall Street analysts to set the chances of a US ban at 80% or higher. In this episode of Votes and Verdicts, Jameel Jaffer, Executive Director of the Knight First Amendment Institute at Columbia University, and a leading US free-s...

Catalysts to Watch – AI Laws, PFAS Trial 02.06.2023

Artificial intelligence regulations, a 3M PFAS contamination trial and FTC antitrust review of Pfizer-Seagen are likely be headline topics in June. This Bloomberg Intelligence litigation and policy outlook episode, hosted by financials litigation senior analyst Elliott Stein, gathers the team to discuss these and other catalysts: Duane Wright on the debt ceiling deal and the Medicaid renewal impac...

Adamantine’s Bays on Sustainable Investing 31.05.2023

There’s been a shift in investing behavior in the energy space, along with a challenging infrastructure environment. In this Votes and Verdicts podcast episode, Adamantine Energy Director of Sustainable Investment Katie Bays joins Bloomberg Intelligence analyst Brandon Barnes for an in-depth discussion about investing in the energy transition. Bays also talks about permitting reform, electrolyzers...

Margaux Hall on Drug Pricing Negotiation 24.05.2023

The prescription drug negotiation provisions in the Inflation Reduction Act fulfill a long-standing policy goal for Democrats and grant the Medicare agency significant regulatory authority to lower prices for high-expenditure drugs, according to Margaux Hall, a partner in the health-care regulatory group at Ropes & Gray. Hall joins Bloomberg Intelligence analysts Duane Wright and Letitia Walke...

Bill Hoagland on Debt-Ceiling Negotiations 15.05.2023

The current debt-ceiling talks are part of a broader effort needed by policymakers to address Washington’s fiscal climate that should include entitlement spending, according to Bill Hoagland, senior vice president for the Bipartisan Policy Center. Hoagland joins Bloomberg Intelligence analysts Duane Wright and Nathan Dean on this episode of the Votes and Verdicts podcast to discuss the debt limit,...

Daniel Horwitz on Trump Indictment Strengths 15.05.2023

How will the prosecution of former President Donald Trump play out? What are the strengths of the indictment? What defenses can we expect? Daniel Horwitz, partner and chair of the litigation department and white-collar defense and investigation practice at McLaughlin & Stern, joins Bloomberg Intelligence analysts Elliott Stein and Nathan Dean on this episode of the Votes and Verdicts podcast t...

Gottlieb on the Future of Crypto Policy, Law 15.05.2023

Jason Gottlieb, Partner and Chair of the digital assets practice at Morrison Cohen, discusses the future of crypto policy and law in depth with Bloomberg Intelligence analysts Elliott Stein and Nathan Dean, on this episode of the Votes and Verdicts podcast, including the paradigm shift that SEC Chair Gary Gensler is missing, and the type of legislation he’d like to see passed. Gottlieb also talks...

The PFAS Problem, Regulatory and Other Issues 15.05.2023

Regulation of PFAS, known as the “Forever Chemicals,” is coming fast to the US, yet huge questions remain about the potentially massive costs of regulation and what effect rules would have on the regulated community. In this Votes & Verdicts podcast, leading remediation expert Jim Claffey, Ph. D., P.E., of Brown and Caldwell, an environmental consulting and engineering firm, joins Bloomberg In...

Crisis of Confidence, Regional Banks’ Future 15.05.2023

How should regulators address the collapse of Silicon Valley Bank and the regional bank crisis? For one, they need to change the way they look at liquidity by factoring in the amount of uninsured deposits that sit on banks’ balance sheets. That will help regulators better understand the risk of a deposit flight like the one that felled SVB, Bloomberg Intelligence’s regional banks analyst Herman Ch...

The FTC’s Evolving Approach to Assessing M&A 15.05.2023

The Federal Trade Commission’s approach to assessing the potential antitrust implications of transactions is evolving and expanding, particularly with respect to the analysis of deals that involve companies that are potential or nascent competitors. The agency has also erected hurdles that make it increasingly difficult for merging companies to navigate their way through the antitrust process and...

The Biggest Tech-Regulation Questions 15.05.2023

Regulation of technology platforms is coming fast to the US and EU, yet huge questions remain about how and when, with heightened scrutiny of tech companies possibly becoming the norm over the coming years, according to Bloomberg Intelligence. In this Votes and Verdicts podcast episode, BI analysts Tamlin Bason and Matthew Schettenhelm tackle the biggest questions about tech regulation in the US a...

Energy's DC Opportunity, Risk with Schneider 15.05.2023

Bloomberg Intelligence analyst Brandon Barnes hosts energy sell-side veteran Timm Schneider for a discussion of the opportunities and risks being generated by federal policymakers for energy infrastructure, including carbon capture, low-carbon fuel standards, export bans, and tax changes. Schneider tells us how traditional energy companies are finding new opportunities in the current policy enviro...

Listen to the Votes & Verdicts podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.